Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

Study Identifier
MAF/AGN/NS/OAB/005
CT.gov Identifier
NCT02072928
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • botulinum toxin Type A
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium * Previous treatment with anticholinergic drugs ineffective * Last BOTOX® treatment ≥18 months.
    Exclusion Criteria:
    * Diagnosis of urinary incontinence less than 9 months. * No anticholinergic drug use in the last 9 months.

    Protocol Summary

    This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.

    Study Locations

    Location
    Status
    Location
    UZA
    Edegem, Belgium, 2650
    Status
    Not applicable
    Location
    CHU de Liège
    Esneux, Belgium, 4130
    Status
    Not applicable
    Location
    UZ Gent
    Ghent, Belgium, 9000
    Status
    Not applicable
    Location
    Centre Hospitalier Regional de Huy
    Huy, Belgium, 4500
    Status
    Not applicable
    Location
    UZ Leuven
    Leuven, Belgium, 3000
    Status
    Not applicable
    Location
    Maria Ziekenhuis Noord-Limburg
    Overpelt, Belgium, 3900
    Status
    Not applicable